Oncolys BioPharma: Announcement of the final results report on the OBP-601 C9-ALS (amyotrophic lateral sclerosis) Phase2a test at the 2024 Annual NEALS Meeting

JPX · Oct 11 07:00

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.